期刊
JOURNAL OF NUCLEAR CARDIOLOGY
卷 19, 期 4, 页码 681-692出版社
SPRINGER
DOI: 10.1007/s12350-012-9547-4
关键词
Regadenoson; adenosine; asthma; COPD; MPI; FEV1
资金
- Astellas Pharma Global Development, Inc.
- Abbott
- Aerovent
- Alcon
- Amgen
- Amphastar
- Boehringer Ingelheim
- Forest
- Genentech
- GlaxoSmithKline
- Map Pharmaceuticals
- Meda
- Medimmune
- Novartis
- Pharmaxis
- Sanofi Aventis
- Schering-Plough Research Institute
- Sepracor (Sunovion)
- Skypharma
- UCB
- Wyeth
Adenosine receptor stress agents for myocardial perfusion imaging (MPI) may cause A(2B) and/or A(3) receptor-mediated bronchoconstriction, of particular concern to physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD). A Phase 4, randomized, double-blind study (NCT00862641) assessed the safety of the selective A(2A) receptor agonist, regadenoson, compared with placebo in subjects with asthma or COPD who represented likely candidates for MPI. Overall, 356 and 176 subjects with asthma and 316 and 151 subjects with COPD received regadenoson and placebo, respectively. The percentage of subjects experiencing a > 15% decrease in FEV1 from baseline to any assessment up to 24 hours post-baseline was not statistically significantly different between the regadenoson and the placebo groups in the asthma or COPD stratum. Dyspnea, the most frequent respiratory adverse event, occurred with higher incidence (P < .0001) in the regadenoson group than the placebo group in the asthma (10.7% vs 1.1%) and COPD (18.0% vs 2.6%) strata. No subjects experienced severe bronchoconstriction, although the occurrence of such reactions with adenosine receptor agonists cannot be ruled out, such that caution is advised. This information may be helpful to physicians selecting a pharmacologic stress agent for MPI in patients with asthma or COPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据